GLP-1 medications: benefits far beyond weight loss

GLP-1 receptor agonists, renowned for metabolic regulation potency, are demonstrating therapeutic benefits that significantly transcend their original weight-loss applications. Recent research documents pleiotropic mechanisms of action: from reduction of major cardiovascular events in type 2 diabetics to potential neuroprotective effects in neurodegeneration, alongside systemic inflammatory markers and improved endothelial function. Peter Attia Drive synthesizes the accumulating evidence suggesting these drugs act on fundamental biological pathways of accelerated aging, not simply on glucose homeostasis. For the longevity-focused reader interested in multimodal interventions, this reframes the risk-benefit profile: these compounds emerge as healthspan-extension tools, not merely cosmetic aids. The open question remains: what is the true ceiling of clinical benefits when evaluated in healthy populations rather than only in patients with established metabolic disease?